Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
Scott T Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A Sackeim
American Journal of Psychiatry 2025 DOI: 10.1176/appi.ajp.20231063 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label study Peer reviewed |
|---|---|
| Population | People with severe treatment-resistant depression |
| Intervention | Psilocybin |
| Topics | Depression Psilocybin |
| Keywords | Psychedelics hallucinogens Psychedelic drugs Drug research Clinical trials Clinical drug studies Depressive disorders Drug/psychotherapy combination Psychopharmacology |
| Citations | 31 |
| Key points | Psilocybin suggests efficacy and safety in severe treatment-resistant depression and supports further study, including consideration of PTSD interaction effects. |
Abstract
This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.